NY-FRAME.IO
11.2.2021 20:32:07 CET | Business Wire | Press release
Frame.io , the world’s leading cloud-based video review and approval platform, today announced Frame.io Camera to Cloud (C2C) , a secure camera-to-cloud workflow that lets customers instantly upload and stream images from on-set cameras to creative post-production teams anywhere in the world. Frame.io C2C represents the largest change in film, television, news and commercial production workflows since the advent of digital filmmaking.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210211005854/en/
Customers can view the launch event on demand at the Frame.io website and sign up for the beta today. Frame.io C2C will be available this spring to all customers at no additional cost. Download the Frame.io C2C press kit here .
Frame.io C2C provides two unique services. First, C2C enables instant proxy uploads the moment cameras stop rolling so editorial can begin within seconds of calling “cut.” In addition, Frame.io C2C can live stream footage to an authorized user’s device on or off set, allowing customers to watch production as it’s happening. This is ideal for productions working during COVID, as it greatly reduces the number of people needed on set. Frame.io C2C lets editorial and other traditionally linear parts of the creative process happen in parallel while footage is still being shot.
Getting footage from a camera into post-production is a time-consuming process that requires backing up files, transferring them to a hard drive, and shipping them to another facility. Frame.io C2C eliminates that, letting customers simultaneously view a live stream of footage as it is being shot, while automatically capturing and uploading proxies as soon as the camera stops rolling.
The camera-to-cloud workflow requires a Frame.io C2C-certified device connected to compatible cameras from Arri, RED and Sony. Once authenticated, certified devices such as the Teradek CUBE 655 and Sound Devices 888 or Scorpio recorders will record, encode, and send timecode-accurate H.264 proxy files with matching filename metadata directly to Frame.io via an encrypted and secure connection using LTE, 5G or WiFi. This allows for near real-time delivery of editable proxy files to a producer, dailies facility, or editor anywhere in the world.
“Frame.io C2C is disruptive technology that changes the traditionally linear filmmaking process, allowing both on-set production and remote post-production teams to work together at the same time,” said Michael Cioni, Global SVP of Innovation at Frame.io. “This level of collaboration brings creative teams together and allows them to work faster and more collaboratively than ever before.”
In addition, Frame.io users with proper authentication credentials can view a live stream of footage while it's being shot from the comfort of their computer, iPhone, or iPad—whether they are on set or halfway around the world. This lets collaborators instantly share ideas to help bring their creative vision to life, while everyone who needs to track production progress can stay informed.
“In today’s socially distanced world—where remote work has become the norm and the number of people on-set is limited—Frame.io C2C is a game changer,” said Emery Wells, CEO of Frame.io. “Camera to Cloud gives film, television, and commercial productions a seamless new way for creative teams to do their best work, no matter where they are.”
Frame.io C2C features best-in-class security with full TPN and SOC 2 Type 2 compliance. Created by the MPAA and CDSA, TPN is the global, industry-wide initiative that defines requirements and best practices for protecting content. Combined with rigorous access controls, Frame.io C2C is an incredibly safe way to share media with authorized viewers and collaborators.
Also introduced today, the new Frame.io Cloud Devices API and C2C certification program enables hardware and software manufacturers to create their own C2C compatible products. Frame.io C2C is launching with three groundbreaking partner integrations from Teradek, Sound Devices, and Colorfront, making it compatible with more than a dozen professional camera systems from RED, Arri, and Sony.
Manufacturers interested in building Frame.io C2C Certified software and hardware can find details at developer.frame.io .
PRICING AND AVAILABILITY
C2C features are included at no additional charge for customers with a paid Frame.io account. Flexible, new monthly enterprise plans let customers and studios purchase the service they need for the duration of their production.
Frame.io C2C is currently in beta and will ship this spring. Customers can apply to participate in the beta program at the Frame.io website. Live streaming features will be available later in 2021.
FRAME.IO C2C LAUNCH PARTNERS
Teradek designs and manufactures high-performance video solutions for broadcast and cinema. A Frame.io authenticated CUBE 655 encoder delivers live streams and camera proxy files directly into Frame.io.
Sound Devices designs and manufactures the world’s leading production sound field recorders. The latest 888 and Scorpio recorders capture and transmit original audio files directly into Frame.io.
Colorfront has developed the world’s first fully cloud dailies platform. Their Express Dailies integration with Frame.io allows labs to instantly access the video and audio assets to create dailies.
ABOUT FRAME.IO
Frame.io is the world’s leading video review and approval platform with over 1 million users. Integrated with most major professional video tools, Frame.io streamlines the creative process by centralizing assets and feedback in the cloud. This allows remote creative teams to collaborate securely and in real time from anywhere in the world.
Conceived and designed in 2015 by video creators Emery Wells and John Traver, Frame.io is intuitive and simple, yet powerful enough for creative professionals, technical administrators, and clients to use with little (or no) training. Frame.io accelerates workflows and eliminates obstacles to creativity. From script or storyboard to dailies through delivery, Frame.io has reinvented the modern video workflow.
Frame.io is backed by industry heavyweights including Insight Partners, FirstMark Capital, and Accel Partners. To learn more please visit http://frame.io .
Watch: Frame.io C2C announcement
Download: Frame.io C2C Press Kit
Watch: What is Frame.io?
View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005854/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom